✦ LIBER ✦

AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity

✍ Scribed by Chresta, C. M.; Davies, B. R.; Hickson, I.; Harding, T.; Cosulich, S.; Critchlow, S. E.; Vincent, J. P.; Ellston, R.; Jones, D.; Sini, P.; James, D.; Howard, Z.; Dudley, P.; Hughes, G.; Smith, L.; Maguire, S.; Hummersone, M.; Malagu, K.; Menear, K.; Jenkins, R.; Jacobsen, M.; Smith, G. C.M.; Guichard, S.; Pass, M.

Book ID: 127374234
Publisher: American Association for Cancer Research
Year: 2009
Tongue: English
Weight: 932 KB
Volume: 70
Category: Article
ISSN: 0008-5472
DOI: 10.1158/0008-5472.can-09-1751

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Identification and characterization of N

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

✍ Maira, S.-M.; Stauffer, F.; Brueggen, J.; Furet, P.; Schnell, C.; Fritsch, C.; B 📂 Article 📅 2008 🏛 American Association for Cancer Research 🌐 English ⚖ 833 KB

A highly selective, orally bioavailable,

A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo

✍ Kenneth R. LaMontagne; Jeannene Butler; Virna B. Borowski; Angel R. Fuentes-Pesq 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 432 KB

Potent, Selective, and Orally Bioavailab

Potent, Selective, and Orally Bioavailable Tricyclic Pyridyl Acetamide N -Oxide Inhibitors of Farnesyl Protein Transferase with Enhanced in Vivo Antitumor Activity

✍ Njoroge, F. George; Vibulbhan, Bancha; Pinto, Patrick; Bishop, W. Robert; Bryant 📂 Article 📅 1998 🏛 American Chemical Society 🌐 English ⚖ 132 KB

SU11248 is a novel FLT3 tyrosine kinase

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

✍ O'Farrell, A.-M. 📂 Article 📅 2003 🏛 American Society of Hematology 🌐 English ⚖ 405 KB

YN968D1 is a novel and selective inhibit

YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo

✍ Shu Tian; Haitian Quan; Chengying Xie; Haiyi Guo; Fangfang Lü; Yongping Xu; Jin 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 527 KB

YN968D1 is a novel and selective inhibit

YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo

✍ Shu Tian; Haitian Quan; Chengying Xie; Haiyi Guo; Fangfang Lü; Yongping Xu; Jin 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 527 KB

Angiogenesis is an important process in cell development, especially in cancer. Vascular endothelial growth factor (VEGF) signaling is an important regulator of angiogenesis. Several therapies that act against VEGF signal transduction have been developed, including YN968D1, which is a potent inhibit